The promising therapeutic outcomes of neoadjuvant immunotherapy with chemotherapy (NAIC) in the treatment of resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) have been confirmed by several clinical trials.
However, the potential benefits of adjuvant therapy for LA-ESCC patients remain unclear.
